Cloud-native financial technology firm Clear Street has expanded its recently launched equity research offering with the addition of healthcare franchise led by Director of Research Mara Goldstein, initially focusing on the biotechnology sector.

According to a press release, the new franchise provides in-depth market analysis and investment insights to the firm’s client base of asset managers, institutions, and professional traders across equities, fixed income, derivatives products, and markets.

It will also complement Clear Street’s prime brokerage and clearing solutions.

To launch coverage, Clear Street has appointed Kaveri Pohlman, PhD and William Maughan, PhD as Managing Directors and Senior Equity Analysts, reporting to Goldstein.

Pohlman’s research coverage will initially focus on oncology and autoimmune disease (I&I), spanning multiple technologies, from cell to gene therapy.

Maughan will bring experience in Equity Research across several therapeutic areas, and will continue to do so at Clear Street, including oncology, ophthalmology and genetic medicine, including RNA technologies.